$PBYI

Puma Biotechnology closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Despite improving net profit margins, analysts forecast an 11.2% annual decline in earnings over the next three years, contrasting sharply with its strong multi-year growth. The company's heavy reliance on its single product, NERLYNX, and its low P/E ratio compared to peers, reflect investor caution regarding future profitability and revenue forecasts.